Antheia’s 2024 in Review: A Year Of Collaboration
As we reflect on 2024, it’s been a significant year of collaboration, with every Antheia employee and partner helping us move closer toward our mission of transforming pharmaceutical supply chains and ending essential medicine shortages. No one person, company, or organization can solve a daunting global problem like drug shortages alone, but we have made […]
Pharma isn’t ready for OTC Narcan demand
Today’s blog will focus on Narcan, a critical opioid overdose rescue drug that is produced from thebaine, Antheia’s first commercial-scale, biomanufactured pharmaceutical ingredient. Read on for more on recent efforts to make Narcan available over the counter, as well as the challenges and opportunities this policy change presents for the pharma industry.
Introducing Ben Kotopka, Director of Data Science
Ben’s work enables teams across the business to track and make sense of more than a decade of R&D data.
Addressing a Root Cause of Global Drug Shortages
The years-long journey medicines take from the farm to the pharmacy is a delicate one, vulnerable to extreme weather, mechanical failures, logistical and shipping delays, and geopolitical issues.
Antheia at SynBioBeta 2024: Scaling Highly Engineered Strains
Antheia was a proud sponsor of this year’s SynBioBeta, the Global Synthetic Biology Conference hosted annually in the San Francisco Bay Area.
Introducing Pavel Aronov, Senior Director, Bioanalytics
Pavel and his team have developed the processes to accurately measure the quantity of our biosynthetic KSMs and APIs produced via biomanufacturing, which is no small feat when working with biological products
U.S. Secretary of State Antony J. Blinken Visits Antheia to Discuss Biotechnology Innovation
In early May, U.S. Secretary of State Antony J. Blinken visited Antheia, HQ in Menlo Park, California for a tour of our labs and a panel discussion with innovators in the biotechnology industry
Antheia CEO Keynotes at OECD Global Forum on Technology: Building our Bio Future
Last week, Antheia CEO and co-founder, Dr. Christina Smolke joined OECD’s Global Forum on Technology: Building our Bio Future as a keynote speaker. OECD (Organization for Economic Co-operation and Development) is an international organization bringing together government, academia, and industry to build global policies that foster prosperity and well-being for all. In her keynote address, […]
Future of Pharma Insights: Q&A with Olon Group
We sat down with Andrea Conforto, VP of CDMO at Olon Biotech.
Introducing Walter Tamulis, Senior Staff Engineer, MSAT
Antheia’s recent commercial breakthrough required the effort of many technical experts who contributed countless hours of hard work. In today’s blog, we are pleased to introduce Walter Tamulis, Senior Staff Engineer of MSAT, a key member of the operations team who was essential in executing our first 116,000L scale run of thebaine and subsequent validation […]